252 related articles for article (PubMed ID: 28569351)
1. Valuing EQ-5D-5L health states 'in context' using a discrete choice experiment.
Cole A; Shah K; Mulhern B; Feng Y; Devlin N
Eur J Health Econ; 2018 May; 19(4):595-605. PubMed ID: 28569351
[TBL] [Abstract][Full Text] [Related]
2. Valuing Health Using Time Trade-Off and Discrete Choice Experiment Methods: Does Dimension Order Impact on Health State Values?
Mulhern B; Shah K; Janssen MF; Longworth L; Ibbotson R
Value Health; 2016; 19(2):210-7. PubMed ID: 27021755
[TBL] [Abstract][Full Text] [Related]
3. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
Ludwig K; von der Schulenburg JG; Greiner W
Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389
[TBL] [Abstract][Full Text] [Related]
4. Does the Introduction of the Ranking Task in Valuation Studies Improve Data Quality and Reduce Inconsistencies? The Case of the EQ-5D-5L.
Ramos-Goñi JM; Rand-Hendriksen K; Pinto-Prades JL
Value Health; 2016 Jun; 19(4):478-86. PubMed ID: 27325340
[TBL] [Abstract][Full Text] [Related]
5. How Should Discrete Choice Experiments with Duration Choice Sets Be Presented for the Valuation of Health States?
Mulhern B; Norman R; Shah K; Bansback N; Longworth L; Viney R
Med Decis Making; 2018 Apr; 38(3):306-318. PubMed ID: 29084472
[TBL] [Abstract][Full Text] [Related]
6. Is Dimension Order Important when Valuing Health States Using Discrete Choice Experiments Including Duration?
Mulhern B; Norman R; Lorgelly P; Lancsar E; Ratcliffe J; Brazier J; Viney R
Pharmacoeconomics; 2017 Apr; 35(4):439-451. PubMed ID: 27873226
[TBL] [Abstract][Full Text] [Related]
7. Health literacy and logical inconsistencies in valuations of hypothetical health states: results from the Canadian EQ-5D-5L valuation study.
Al Sayah F; Johnson JA; Ohinmaa A; Xie F; Bansback N;
Qual Life Res; 2017 Jun; 26(6):1483-1492. PubMed ID: 28124280
[TBL] [Abstract][Full Text] [Related]
8. A pilot discrete choice experiment to explore preferences for EQ-5D-5L health states.
Norman R; Cronin P; Viney R
Appl Health Econ Health Policy; 2013 Jun; 11(3):287-98. PubMed ID: 23649892
[TBL] [Abstract][Full Text] [Related]
9. The EQ-5D-5L valuation study in Korea.
Kim SH; Ahn J; Ock M; Shin S; Park J; Luo N; Jo MW
Qual Life Res; 2016 Jul; 25(7):1845-52. PubMed ID: 26961008
[TBL] [Abstract][Full Text] [Related]
10. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
[TBL] [Abstract][Full Text] [Related]
11. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
[TBL] [Abstract][Full Text] [Related]
13. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.
Oppe M; Devlin NJ; van Hout B; Krabbe PF; de Charro F
Value Health; 2014 Jun; 17(4):445-53. PubMed ID: 24969006
[TBL] [Abstract][Full Text] [Related]
14. Head-to-Head Comparison of EQ-5D-3L and EQ-5D-5L Health Values.
Selivanova A; Buskens E; Krabbe PFM
Pharmacoeconomics; 2018 Jun; 36(6):715-725. PubMed ID: 29623559
[TBL] [Abstract][Full Text] [Related]
15. Test-Retest Reliability of EQ-5D-5L Valuation Techniques: The Composite Time Trade-Off and Discrete Choice Experiments.
Purba FD; Hunfeld JAM; Timman R; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Passchier J; Busschbach JJV
Value Health; 2018 Oct; 21(10):1243-1249. PubMed ID: 30314626
[TBL] [Abstract][Full Text] [Related]
16. The EQ-5D-5L Valuation study in Thailand.
Pattanaphesaj J; Thavorncharoensap M; Ramos-Goñi JM; Tongsiri S; Ingsrisawang L; Teerawattananon Y
Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):551-558. PubMed ID: 29958008
[TBL] [Abstract][Full Text] [Related]
17. Valuing health-related quality of life: An EQ-5D-5L value set for England.
Devlin NJ; Shah KK; Feng Y; Mulhern B; van Hout B
Health Econ; 2018 Jan; 27(1):7-22. PubMed ID: 28833869
[TBL] [Abstract][Full Text] [Related]
18. Dutch Tariff for the Five-Level Version of EQ-5D.
M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
[TBL] [Abstract][Full Text] [Related]
19. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
[TBL] [Abstract][Full Text] [Related]
20. German Value Set for the EQ-5D-5L.
Ludwig K; Graf von der Schulenburg JM; Greiner W
Pharmacoeconomics; 2018 Jun; 36(6):663-674. PubMed ID: 29460066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
